Press Release
« Back
TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology
May 17, 2017
Oral Presentation:
- Title: Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study
° Abstract Number: 7504
° Presentation Date & Time:Saturday, June 3, 2017 3:00 PM -6:00 PM CT
° Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
° Presenter:Jeffrey P. Sharman , MD
Poster Discussion Presentation:
- Title: Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with
advanced CLL and NHL
° Abstract Number: 7511
° Presentation Date & Time:Monday, June 5, 2017 8:00 AM-11:30 AM CT (Poster Viewing);1:15 PM-2:30 PM CT (Poster Discussion)
° Session Title: Poster Discussion Session, Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
° Presenter:Loretta Nastoupil , MD
Trials in Progress Poster Presentation:
- Title: KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy
° Abstract Number: TPS7569
° Presentation Date & Time:Monday, June 5, 2017 8:00 AM-11:30 AM CT
° Session Title: Poster Session, Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
° Presenter:Colleen Dorsey , BSN, RN
Following each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company's website at www.tgtherapeutics.com.
TG THERAPEUTICS INVESTOR & ANALYST EVENT
ABOUT
Cautionary Statement
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. In addition to the risk factors identified from time to time in our reports filed with the Securities and Exchange Commission, factors that could cause our actual results to differ materially are the following: our ability to successfully and cost effectively complete preclinical and clinical trials; the risk that early clinical trial results, that may have supported the acceptance of our data for presentation or influenced our decision to proceed with additional clinical trials, will not be reproduced in future studies or in the final presentations; the risk that the combination of TG-1101 and TGR-1202, referred to as TG-1303 and being studied in the UNITY clinical trials, will not prove to be a safe and efficacious combination or backbone for triple and/or quad therapies; the risk that any interim analyses from ongoing clinical trials will not produce the desired or predicted result. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
TGTX - G
CONTACT:Source:Jenna Bosco Vice President- Investor RelationsTG Therapeutics, Inc. Telephone: 212.554.4351 Email: ir@tgtxinc.com
News Provided by Acquire Media